Impact of Vitamin E supplementation on lipoprotein peroxidation and composition in Type 1 diabetic patients treated with Atorvastatin

Atherosclerosis

Volumn 175, Issue 2, 2004, Pages 369-376

  Manuel Y Keenoy, Begoña ^a   Vinckx, Marleen ^a   Vertommen, Jan ^a   Van Gaal, Luc ^b   De Leeuw, Ivo ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

tocopherol; Atorvastatin; Lipoprotein; Peroxidation; Type 1 diabetes mellitus

Indexed keywords

ALPHA TOCOPHEROL; ATORVASTATIN; CHOLESTEROL; COPPER; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; PLACEBO; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD GLUCOSE MONITORING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPID PEROXIDATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ADULT; AGED; ALPHA-TOCOPHEROL; ANTIOXIDANTS; DIABETES MELLITUS, TYPE 1; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID PEROXIDATION; LIPOPROTEINS; MALE; MIDDLE AGED; PYRROLES;

EID: 3242731551     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2004.04.005     Document Type: Article

References (70)

1. Kannel W., McGee D. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Cares. 2:1979;120-126
2. Haffner S.M., Lehto S., Ronnemaa T. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339:1998;229-234
3. Syvanne M., Taskinen M.R. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet. 350(Suppl. 1):1997;SI20-SI23
4. Koya D., King George L. Protein kinase C activation and the development of diabetic complications. Diabetes. 47:1998;859-866
5. Nishikawa T., Edelstein D., Du X.L., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 404:2000;787-790
6. Brownlee M. Glycation and diabetic complications. Diabetes. 43:1994;836-841
7. Wolff S.P. Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br. Med. Bull. 49:1993;642-652
8. Tsai E.C., Hirsch I.B., Brunzell J.D., Chait A. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes. 43:1994;1010-1014
9. Rabini R.A., Fumelli P., Galassi R., et al. Increased susceptibility to lipid oxidation of low-density lipoproteins and erythrocyte membranes from diabetic patients. Metabolism. 43:1994;1470-1474
10. Griesmacher A., Kindhauser M., Andert S.E., et al. Enhanced serum levels of thiobarbituric-acid-reactive substances in diabetes mellitus. Am. J. Med. 98:1995;469-475
11. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature. 362:1993;801-809
12. Grundy S.M., Benjamin I.J., Burke G.L., et al. Diabetes and cardiovascular disease. A statement for health care professionals from the American Heart Association. Circulation. 100:1999;1134-1146
13. Rowland Y.K., Yeo W.W. Lipid lowering in patients with diabetes mellitus: what coronary heart disease risk threshold should be used? Heart. 87:2002;423-427
14. Bellosta S., Ferri N., Arnaboldi L., et al. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care. 23(Suppl. 2):2000;B72-B78
15. Pyorala K., Pedersen T.R., Kjekhus J., et al. Cholesterol-lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 20:1997;614-620
16. Goldberg R.B., Mellies M.J., Scks F.M., et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 98:1998;2513-2519
17. Kanters S.D., Algra A., de Bruint T.W., Erkelens D.W., Banga J.D. Intensive lipid-lowering strategy in patients with diabetes mellitus. Diabetes Med. 16:1999;500-508
18. Winocour P.H., Durrington P.N., Ishola M., Anderson D.C., Cohen H. Influence of proteinuria on vascular disease, blood pressure, and lipoproteins in insulin dependent diabetes mellitus. Br. Med. J. (Clin. Res. Ed.). 294:1987;1648-1651
19. Groop P.H., Elliott T., Ekstrand A., et al. Multiple lipoprotein abnormalities in type I diabetic patients with renal disease. Diabetes. 45:1996;974-979
20. Zhang A., Vertommen J., Van Gaal L., De Leeuw I. A rapid and simple method for measuring the susceptibility of low-density-lipoprotein and very-low-density lipoprotein to copper-catalysed oxidation. Clin. Chim. Acta. 227:1994;159-173
21. Engelen W., Manuel y Keenoy B.M., Vertommen J., De Leeuw I. Effects of long-term supplementation with moderate pharmacologic doses of Vitamin E are saturable and reversible in patients with type 1 diabetes. Am. J. Clin. Nutr. 72:2000;1142-1149
22. Manuel y Keenoy B., Van Campenhout C., Vertommen J., De Leeuw I. Effects of Atorvastatin on LDL sub-fractions and peroxidation in type 1 diabetic patients: a randomised double-blind placebo-controlled study. Diabetes Metab. Res. Rev. 19:2003;478-486
23. Friedewald W.T., Levy M., Frederickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin. Chem. 18:1972;499-502
24. Caye-Vaugien C., Krempf M., Lamarche P., Charbonnel B., Pieri J. Determination of α-tocopherol in plasma, platelets and erythrocytes of type I and type II diabetic patients by HPLC. Int. J. Vitam. Nutr. Res. 60:1990;324-330
25. Nielsen F., Mikkelsen B.B., Nielsen J.B., Andersen H.R., Grandjean P. Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin. Chem. 43:1997;1209-1214
26. Mullen M.J., Wright D., Donald A.E., et al. Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. J. Am. Coll. Cardiol. 36:2000;410-416
27. Fuller C., Chandalia M., Garg A., Grundy S.M., Jialal I. RRR-alpha tocopherol acetate supplementation at pharmacological doses decreases LDL oxidation susceptibity but not protein glycation in diabetes mellitus. Am. J. Clin. Nutr. 63:1996;753-759
28. Jain S.K., McVie R., Jaramillo J.J., Palmer M., Smith T. Effect of modest Vitamin E supplementation on blood glycated hemoglobin and triglyceride levels and red cell indices in type I diabetic patients. J. Am. Coll. Nutr. 15:1996;458-461
29. Meydani S.N., Meydani M. Assessment of the safety of supplementation with different amounts of Vitamin E in healthy older adults. Am. J. Clin. Nutr. 68:1998;311-318
30. Tsai A.C., Kelley J.J., Peng B. Study on the effect of megavitamin E supplementation in man. Am. J. Clin. Nutr. 31:1978;831-837
31. Cheung M.C., Zhao X.Q., Chait A., Albers J.J., Brown B.G. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler. Thromb. Vasc. Biol. 21:2001;1320-1326
32. Vandewoude M.F.J., Vandewoude M.G., Van Gaal L., De Leeuw I. Vitamin E status in normocholesterolemic and hypercholesteremic diabetic patients. Acta Diabetol. Latina. 24:1987;133-139
33. Horwitt M.K., Harvey C.C., Dahm C.H. Jr., Searcy M.T. Relationship between tocopherol and serum lipid levels for determination of nutritional adequacy. Ann. N. Y. Acad. Sci. 203:1972;223-236
34. Traber M.G., Jialal I. Measurement of lipid-soluble vitamins - further adjustment needed? Lancet. 355:2000;2013-2014
35. Traber M.G. Determinants of plasma Vitamin E concentrations. Free Radic. Biol. Med. 16:1994;229-239
36. Pryor W.A. Vitamin E and heart disease: basic science to clinical intervention trials. Free Radic. Biol. Med. 28:2000;141-164
37. Esterbauer H., Rotheneder M., Striegl G., Waeg G. Vitamin E and other Lipophilic Antioxidants Protect LDL against Oxidation. Fat Sci. Technol. 8:1989;316-324
38. Steinberg D., Witztum J.L. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation. 105:2002;2107-2111
39. Devaraj S., Adams-Huet B., Fuller C.J., Jialal I. Dose-response comparison of RRR-alpha-tocopherol and all-racemic alpha-tocopherol on LDL oxidation. Arterioscler. Thromb. Vasc. Biol. 17:1997;2273-2279
40. Simons L.A., Von Konigsmark M., Balasubramaniam S. What dose of Vitamin E is required to reduce susceptibility of LDL to oxidation? Aust. N. Z. J. Med. 26:1996;496-503
41. Reaven P. Dietary and pharmacologic regimens to reduce lipid peroxidation in non- insulin-dependent diabetes mellitus. Am. J. Clin. Nutr. 62:1995;1483S-1489S
42. Frei B., Gaziano J.M. Content of antioxidants, preformed lipid hydroperoxides, and cholesterol as predictors of the susceptibility of human LDL to metal-ion-dependent and -independent oxidation. J. Lipid Res. 34:1993;2135-2145
43. Schuster B., Prassl R., Nigon F., Chapman M.J., Laggner P. Core lipid structure is a major determinant of the oxidative resistance of low density lipoprotein. Proc. Natl. Acad. Sci. USA. 92:1995;2509-2513
44. Scheffer P.G., Bakker S.J., Popp-Snijders C., et al. Composition of LDL as determinant of its susceptibility to in vitro oxidation in patients with well-controlled type 2 diabetes. Diabetes Metab. Res. Rev. 17:2001;459-466
45. Kleinveld H.A., Naber A.H., Stalenhoef A.F., Demacker P.N. Oxidation resistance, oxidation rate, and extent of oxidation of human low-density lipoprotein depend on the ratio of oleic acid content to linoleic acid content: studies in Vitamin E deficient subjects. Free Radic. Biol. Med. 15:1993;273-280
46. Thomas S.R., Neuzil J., Stocker R. Cosupplementation with coenzyme Q prevents the prooxidant effect of alpha-tocopherol and increases the resistance of LDL to transition metal-dependent oxidation initiation. Arterioscler. Thromb. Vasc. Biol. 16:1996;687-696
47. Alleva R., Tomasetti M., Battino M., Curatola G., Littarru G.P., Folkers K. The roles of coenzyme Q10 and Vitamin E on the peroxidation of human low density lipoprotein subfractions. 20. Proc. Natl. Acad. Sci. USA. 92:1995;9388-9391
48. Ghirlanda G., Oradei A., Manto A., et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J. Clin. Pharmacol. 33:1993;226-229
49. Lankin V.Z., Tikhaze A.K., Konovalova G.G., et al. Intensification of free radical oxidation of low-density lipoproteins in the plasma of patients with ischemic heart disease receiving β-hydroxy-β-methylglutaryl- coenzyme A reductase inhibitor cerivastatin and inhibition of low-density lipoprotein peroxidation with antioxidant probucol. Bull. Exp. Biol. Med. 134:2002;39-42
50. Ohmura H., Mokuno H., Sawano M., et al. Lipid compositional differences of small, dense low-density lipoprotein particle influence its oxidative susceptibility: possible implication of increased risk of coronary artery disease in subjects with phenotype B. Metabolism. 51:2002;1081-1087
51. Pontrelli L., Parris W., Adeli K., Cheung R.C. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism. 51:2002;334-342
52. Lal M.A., Korner A., Matsuo Y., et al. Combined antioxidant and COMT inhibitor treatment reverses renal abnormalities in diabetic rats. Diabetes. 49:2000;1381-1389
53. Regnstrom J., Nilsson J., Tornvall P., Landou C., Hamsten A. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet. 339:1992;1183-1186
54. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11:1991;81-128
55. Gutteridge J.M., Halliwell B. The measurement and mechanism of lipid peroxidation in biological systems. Trends Biochem. Sci. 15:1990;129-135
56. de Zwart L.L., Meerman J.H., Commandeur J.N., Vermeulen N.P. Biomarkers of free radical damage applications in experimental animals and in humans. Free Radic. Biol. Med. 26(1,2):1999;202-226
57. Dierckx N., Horvath G., van Gils C., et al. Oxidative stress status in patients with diabetes mellitus: relationship to diet. Eur. J. Clin. Nutr. 57:2003;999-1008
58. Ide T., Tsutsui H., Ohashi N., et al. Greater oxidative stress in healthy young men compared with premenopausal women. Arterioscler. Thromb. Vasc. Biol. 22(3):2002;438-442
59. Jain S.K., McVie R., Smith T. Vitamin E supplementation restores glutathione and malondialdehyde to normal concentrations in erythrocytes of type 1 diabetic children. Diabetes Care. 23:2000;1389-1394
60. Winklhofer-Roob B., Esterbauer H. Impaired resistance to oxidation of low density lipoprotein in cystic fibrosis: improvement during Vitamin E supplementation. Free Radic. Biol. Med. 19:2000;725-733
61. Brown K.M., Morrice P.C., Arthur J.R., Duthie G.G. Effects of Vitamin E supplementation on erythrocyte antioxidant defence mechanisms of smoking and non-smoking men. Clin. Sci. (Colch.). 91:1996;107-111
62. Keith M.E., Jeejeebhoy K.N., Langer A., et al. A controlled clinical trial of Vitamin E supplementation in patients with congestive heart failure. Am. J. Clin. Nutr. 73:2001;219-224
63. Meagher E.A., Barry O.P., Lawson J.A., Rokach J., FitzGerald G.A. Effects of Vitamin E on lipid peroxidation in healthy persons. JAMA. 285:2001;1178-1182
64. Heinecke J.W. Is the emperor wearing clothes? Clinical trials of Vitamin E and the LDL oxidation hypothesis. Arterioscler. Thromb. Vasc. Biol. 21:2001;1261-1264
65. Oguogho A., Sinzinger H. Isoprostanes in atherosclerosis. J. Physiol. Pharmacol. 51:2000;673-682
66. Stephens N., Parsons A., Mitchinson M.J. Randomised controlled trial of Vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 347:1996;781-786
67. Boaz M., Smetana S., Weinstein T., et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 356:2000;1213-1218
68. Yusuf S., Dagenais G., Pogue J., Bosch J., Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342:2000;154-160
69. HPS. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
70. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345:2001;1583-1592